TITLE

Review: Methylxanthines are not effective for acute exacerbations of chronic obstructive pulmonary disease

PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p60
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article determines the effectiveness of addition of methylxanthines to standard treatments of patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). Studies were selected if they were randomized controlled trials that compared methylxanthines with placebo for acute exacerbations of COPD; treatment occurred in the emergency department (ED) or immediately after admission to hospital; and patients had confirmed COPD with an exacerbation that required presentation to an ED, acute care setting, or hospital. In patients with acute exacerbations of chronic obstructive pulmonary disease, methylxanthines do not improve lung function after 2 hours, clinical outcomes, or symptoms and increase nausea or vomiting.
ACCESSION #
13221822

 

Related Articles

  • Review: Hospital-at-home care does not increase mortality or readmission rates in acute exacerbations of COPD: COMMENTARY. Jacobs, Michael B. // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p59 

    Chronic obstructive pulmonary disease (COPD) is a common illness that is costly to treat, especially when hospitalization is required for acute exacerbations. Total estimated costs in 1993 in the United States were $24 billion; 60% of these costs were directly related to hospital-based care....

  • Commentary. Rees, P. John // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article comments on a study by A. D. Smith and colleagues to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic...

  • Using exhaled NO concentrations to adjust inhaled corticosteroid dose maintained asthma control and reduced the dose. Smith, A. D.; Cowan, J. O.; Brassett, K. P.; Taylor, R. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article reports on a study to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic asthma. Patients aged 12-75...

  • The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? van der Molen, Thys; Kocks, Janwillem W. H. // Primary Care Respiratory Society UK;5/20/2014, p1 

    The authors reflect on the safety and effectiveness of inhaled corticosteroids (ICS) as well as the possible benefits of ciclesonide. They mention that the synthetic steroids are considered the basic treatment for asthma and prescribed by physicians for handling chronic obstructive pulmonary...

  • The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? van der Molen, Thys; Kocks, Janwillem W. H. // Primary Care Respiratory Society UK;6/1/2014, p1 

    The author reflects on the effectiveness and safety of using ciclesonide, an inhaled corticosteroids (ICS) agent on patients with asthma. Topics include the prescription of ICS in patients with chronic obstructive pulmonary disease (COPD), the introduction of ICS in the clinical prctice in 1970,...

  • Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Mirici, A.; Meral, M.; Akgun, M. // Clinical Drug Investigation;2003, Vol. 23 Issue 1, p55 

    Objective: To compare the efficacy and safety of nebulised budesonide and systemic corticosteroid in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Design: Randomised, double-blind, placebo-controlled, parallel-group trial. Patients and interventions: A...

  • Triple therapy benefits COPD patients.  // Australian Journal of Pharmacy;Mar2010, Vol. 91 Issue 1078, p78 

    The article reports on the study which reveals that combining an anticholinergic with an inhaled corticosteroid and a longacting beta2-agonist may provide clinical benefits in patients with chronic obstructive pulmonary disease.

  • Does Inhaled Budesonide Produce Benefits in COPD? Walling, Anne D. // American Family Physician;11/1/1999, Vol. 60 Issue 7, p2156 

    Presents an evaluation on the treatment of chronic obstructive pulmonary disease (COPD) by inhaled corticosteroids. Long-term effects of inhaled budesonide in patients with COPD; Need for differentiation between asthma and COPD in patients with pulmonary symptoms.

  • COPD combo success.  // Nature Reviews Drug Discovery;Oct2013, Vol. 12 Issue 10, p728 

    The article focuses on several drugs for the treatment of chronic obstructive pulmonary disease (COPD), which include the inhaled corticosteroids, long-acting β2-adregeneric receptor agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs.)

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics